William Hampton Bradley MD

Obstetrics & Gynecology•Milwaukee, WI

Gynecologic Oncology

Assistant Professor, Obstetrics & Gynecology, Medical College of Wisconsin

Join to View Full Profile

Medical College of Wisconsin8701 Watertown Plank RoadMilwaukee, WI 53226
Phone+1 414-805-6606
Fax+1 414-805-2233

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Gynecologic Oncology, 2005 - 2008
University of MinnesotaResidency, Obstetrics and Gynecology, 2000 - 2004
University of Minnesota Medical SchoolClass of 2000

Certifications & Licensure

WI State Medical License 2008 - 2025
NY State Medical License 2005 - 2008
MN State Medical License 2002 - 2006
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
ACTIVE_NOT_RECRUITING
PHASE3
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Start of enrollment: 2012 Jun 01
Unknown status
Not Applicable
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2012 Jul 09
Completed
Phase 1
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 3
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) Start of enrollment: 2019 Jul 19
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA ...
David Mutch, Athina Voulgari, Xian Marissa Chen, William H Bradley, Ana Oaknin
Cancer. 2024-06-01
1 citations
Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer.
Denise Uyar, Chad M Michener, Erin Bishop, Elizabeth Hopp, Pippa Simpson
Frontiers in Oncology. 2024-01-01
2 citations
Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies.
Lindsey A McAlarnen, Christina Small, Lauren Tostrud, Amy Y Pan, Beth Erickson
Brachytherapy. 2023-06-30

Press Mentions

UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive ManagementSeptember 10th, 2024
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive ManagementSeptember 9th, 2024
Different Outcomes for Oshkosh Sisters in Cancer Drug TrialApril 30th, 2021